
European biotech venture builder Kurma closes €215m fund
Kurma Partners, a European healthcare venture capital firm, has announced the final closing of Biofund IV at €215 million. The new fund will support the discovery and development of disruptive therapeutic solutions for severe or incurable diseases. Building on the €160 million Biofund III, this successful fundraise has increased the… Read More














